# Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus

> **NCT02143648** · PHASE2,PHASE3 · COMPLETED · sponsor: **Trevi Therapeutics** · enrollment: 373 (actual)

## Conditions studied

- Uremic Pruritus
- Pruritus

## Interventions

- **DRUG:** nalbuphine HCl ER tablets 60 mg BID
- **DRUG:** nalbuphine HCl ER tablets 120mg BID
- **DRUG:** Placebo tablets BID

## Key facts

- **NCT ID:** NCT02143648
- **Lead sponsor:** Trevi Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 373 (ACTUAL)
- **Last updated:** 2025-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02143648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02143648, "Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02143648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*